Telaprevir (Incivo®)

Assessment Status Assessment process complete
Drug Telaprevir
Brand Incivo®
Indication As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.
Assessment Process
Rapid review commissioned 28/10/2011
Rapid review completed 02/11/2011
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 08/11/2011
NCPE assessment completed 19/01/2012
NCPE assessment outcome Reimbursement Recommended

We consider telaprevir (Incivo®) a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.

Technical Summary